1.


PTO/SB/05 (08-00)

Approved for use through 10/31/2002, OMB 0651-0032 U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

## UTILITY PATENT APPLICATION **TRANSMITTAL**

APPLICATION ELEMENTS

Attorney Docket No. GA0182US First Inventor or Application Identifier | Landes, Gregory M ISOLATION AND IDENTIFICATION OF SECRETED PROTEINS

Assistant Commissioner for Patents O

only for new nonprovisional applications under 37 C.F.R. § 1.53(b))	Express Mail Label No.	EL 734 663 705 US

See MPEP chapter 600 concerning design patent application contents.	Washington, DC 20231
Fee Transmittal Form (e.g., PTO/SB/17), PTG-Bs/06 (Submit an original and a duplicate for the processing) 1-9 a Applicant claims small entity status. See 37 CFR 1.27  Specification - Describes title of the Invention (preferred arrangement set forth below) - Describes title of the Invention - Statement Regarding Fed sponsored R & D - Background of the Invention - Biet Summary of the Invention	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nuclectide and/or Amino Acid Sequence Submission (Il applicable, all necessary) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. Deper 1 sheet c. Statements verifying identity of above copies 2 shts.
- Brief Description of the Drawings (If filed) - Detailed Description - Claim(s) - Claim	Assignment Papers (cover sheet & document(s))     T.C.F.R.§3.73(b)Statement   Power of (when there is an assignee)   Attorney       English Translation Document (if applicable)       Information Disclosure   Copies of IDS       Statement (IDS)/PTO-1449
b. ☐ copy from a prior application (37 CFR 1.63 (d))  (for a continuation/divisional with Box 17 completed)  ☐ DELETION OF INVENITORI(S)  Signed elatement attached selering invertor(s) named in the prior application, see 37 CFR 1 8d(d)(2) and 1 38(d)(2) and 1	Preliminary Amendment 2 sheets     Amendment 2 sheets     She
17. If a CONTINUING APPLICATION, check appropriate box, and supply or in an Application Data Sheet under 37 CFF 1: 76  Continuation   Divisional   Divisional   Continuation-in-part (prior application information. Examinar   Examinar   Experiment   Examinar   Exami	CIP) of prior application No/ Group / Art Unit

under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference.

The incorporation <u>can only</u> be relied upon when a portion has been inadvertently omitted from the submitted application parts.

			17. CON	HESP OF	IDENCE ADDRES			
☑ Custo	omer Number or B		insert Custome		ach bar code label he	o ere)	· 🗆	Correspondence address below
Name	GENZYME C	ORPORATION		2453	36			
Ivanie			PATE	NT_TRADEM	ARK OFFICE			
Address	15 PLEASAN	IT STREET CONN	NECTOR					
Address	P.O. BOX 93	22						
City	FRAMINGHAM		Sta	ate	MA		Code	01701-9322
Country	USA		Telephone	9	508-872-8400		Fax	508-872-5415
Name (Print/Type) DEBORAH A. DU		UGAN		Registration No. (A	httorney/A	(gent)	37.315	

Signature Burden Hour Statement This form is estimated to lack 02 hours to complye Time will vary depending upon the needs of the individual case Any comments on the amount of time you are required to complete this form solud be sent to the Chief Information Officer, U.S. Patert and Trademark. Office, Washington, D. 20231 DO NOT SERVO FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 2023.

Date

PTO/SB/17 (11-00)
Approved for use through 10/31/2002. OMB 0685-109
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
uired to respond to a collection of information unless it displays a valid OMB control number.

# **FEE TRANSMITTAL** for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

Complete if Known						
Application Number	Unassigned					
Filing Date	01 February 2001					
First Named Inventor	Landes, Gregory M.					
Examiner Name	Unassigned					
Group Art Unit	Unassigned					
Attemos Dooket No	CAMPATIC					

		_		,	JCKEL I			
METHOD OF PAYMENT	FEE CALCULATION (continued)							
The Commissioner is hereby authorized to charge indicated fees and credit any overneyments to			3. ADDITIONAL FEES					
Deposit Deposit	payments to	Large E Fee	ntity Fee	Small I	Fee		Fee Description	Fee Paid
Account Number 07-1074	- 11	Code 105	(\$)	Code 205	(\$)	Surch	arge - late filing fee or oath	ree raid
Denosit		127	50	205	25		arge - late provisional filing fee or cover	
Account Name GENZYME CORPO	DRATION	127				sheet	* '	
		139	130	139			English specification	
Under 37 CFR §§ 1 16 and 1 17			2,520				ng a request for ex parte reexamination	
Applicant claims small entity status See 37 CFR § 1 27		112	920*	112	920*	Reque	esting publication of SIR prior to Examiner	
2. Payment Enclosed:		113	1,840*	113	1,840*	Reque	esting publication of SIR after Examiner	
Check Credit card M	loney Other	115	110	215	55	Extens	sion for reply within first month	
FEE CALCULATION	v	116	390	216	195	Extens	sion for reply within second month	
BASIC FILING FEE		117	890	217	445	Exten:	sion for reply within third month	
Large Entity Small Entity		118	1,390	218	695	Extens	sion for reply within fourth month	
Fee Fee Fee Fee Description Code (\$) Code (\$)	Fee Paid	128	1,890	228	945	Exten:	sion for reply within fifth month	
101 710 201 355 Utility filing fee	710.00	119	310	219			of Appeal	
106 320 206 160 Design filing fee		120	310	220			a brief in support of an appeal	
107 490 207 245 Plant filing fee		121	270	221			est for oral hearing	
108 710 208 355 Reissue filing fee		138	1,510	138	1,510	Petitio	n to institute a public use proceeding	
114 150 214 75 Provisional filing fe	эе	140	110	240	55	Petitio	n to revive - unavoidable	
SUBTOTAL (1)	\$710.00	141	1,240	241	620	Petitic	n to revive - unintentional	
2. EXTRA CLAIM FEES		142	1,240	242	620	Utility	issue fee (or reissue)	
Fe	ee from	143	440	243	220	Desig	n issue fee	
	below Fee Paid 18.00 = 252.00	144	600	244			issue fee	
Total Claims 34 -20** = 14 X 18.00 = 252.00 Independent 1 - 3** = 0 X = 0.00		122	130	122			ons to the Commissioner	
Claims	270.00 = 270.00	123	50	123			ssing fee under 37 CFR § 1 17(q)	
Large Entity Small Entity		126	180	126	180	Subm	ission of Information Disclosure ment	
Fee Fee Fee Fee Fee Descr Code (\$) Code (\$)	ription	581	40	581	40	Recor (times	ding each patent assignment per property number of properties)	
103 18 203 9 Claims in excess		146	710	246	355	Filing (37 CI	a submission after final rejection FR § 1.129(a))	
	ms in excess of 3 ent claim, if not paid	149	710	249	355	Fores	ach additional invention to be examined FR § 1 129(b))	
109 80 209 40 " Reissue Indep	endent claims	179	710	279		Reque	est for Continued Examination (RCE)	
over original pe		169	900	169	900	Reque	est for expedited examination esign application	
110 18 210 9 ** Reissue claims in excess of 20 and over original patent			Other fee (specify)				coign approarion	
SUBTOTAL (2)	l							
**or number previously paid, if greater, For Reissues, see above			duced i	y Bası	Filing	Fee Pa	aid SUBTOTAL (3)	

508-270-2598 37,315 Name (Print/Type) DEBORAH A. DUGAN Telephone 101 101 Signature

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form sixual be sent to the Chell information Officer, Patient and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patients, Washington, DC 20231

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Landes, Gregory M.

APPLICATION NO:

Unassigned

GROUP NO: Unassigned

FILING DATE:

February 1, 2001

EXAMINER: Unassigned

TITLE:

ISOLATION AND IDENTIFICATION OF SECRETED PROTEINS

Assistant Commissioner for Patents Washington, D.C. 20231

#### CERTIFICATE OF MAILING BY "EXPRESS MAIL"

I hereby certify that this paper or fee is being deposited on February 1, 2001 with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 as Express Mail Labél No. El. 734 663 705 US and is addressed to: Assistant Commissioner for Fetents, Washington, D.C. 2023 1

ebludly 1, 2001

MKYN ( Taryn/Antalek

## SUBMISSION OF PAPER COPY AND/OR COMPUTER READABLE COPY OF SEQUENCE LISTING FOR INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCES

Pursuant to 37 C.F.R.  $\S \S 1.821 - 1.824$  Applicant submits herewith a paper copy and a computer readable copy of the Sequence Listing for the above-identified application.

### Statement

I hereby state that (a) the content of the paper and computer readable copy submitted herewith are the same; (b) the content of the computer readable copy submitted herewith is the same as the Sequence Listing appearing on page 53 of the

# 145 CM 145 CM 145 CM

In re: Landes Filed: February 1, 2001 Page 2

original specification of U.S. Provisional Application Serial Number 60/180,582 as filed on February 4, 2000; and (c) this submission includes no new matter.

Respectfully submitted,

Deborah A. Dugan Registration No. 37,315

Genzyme Corporation 15 Pleasant Street Connector P.O. Box 9322 Framingham, Massachusetts 01701-9322

Telephone: (508) 270-2598 Facsimile: (508) 872-5415